Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Alerts
  • Advertising/recruitment
  • Subscribe
  • Contact
  • Current Issue
  • Past Issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews ...
    • 100th Anniversary of Insulin's Discovery (Jan 2021)
    • Hypoxia-inducible factors in disease pathophysiology and therapeutics (Oct 2020)
    • Latency in Infectious Disease (Jul 2020)
    • Immunotherapy in Hematological Cancers (Apr 2020)
    • Big Data's Future in Medicine (Feb 2020)
    • Mechanisms Underlying the Metabolic Syndrome (Oct 2019)
    • Reparative Immunology (Jul 2019)
    • View all review series ...
  • Viewpoint
  • Collections
    • Recently published
    • In-Press Preview
    • Commentaries
    • Concise Communication
    • Editorials
    • Viewpoint
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Author's Takes
  • Recently published
  • In-Press Preview
  • Commentaries
  • Concise Communication
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Alerts
  • Advertising/recruitment
  • Subscribe
  • Contact
T cell homeostatic proliferation elicits effective antitumor autoimmunity
Wolfgang Dummer, … , Ralph A. Reisfeld, Argyrios N. Theofilopoulos
Wolfgang Dummer, … , Ralph A. Reisfeld, Argyrios N. Theofilopoulos
Published July 15, 2002
Citation Information: J Clin Invest. 2002;110(2):185-192. https://doi.org/10.1172/JCI15175.
View: Text | PDF
Article Aging

T cell homeostatic proliferation elicits effective antitumor autoimmunity

  • Text
  • PDF
Abstract

Research Article

Authors

Wolfgang Dummer, Andreas G. Niethammer, Roberto Baccala, Brian R. Lawson, Norbert Wagner, Ralph A. Reisfeld, Argyrios N. Theofilopoulos

×

Figure 4

Options: View larger image (or click on image) Download as PowerPoint
Proliferation and immunohistochemistry of tumor-infiltrating T cells. (a...
Proliferation and immunohistochemistry of tumor-infiltrating T cells. (a) Groups of C57BL/6 mice (Thy1.2+) were sublethally irradiated, challenged with melanoma cells, and transfused with 5 × 106 CFSE-labeled syngeneic B6.PL (Thy1.1+) LN cells. Four weeks later, single cell suspensions of host LN, spleen, and tumor tissue were analyzed for division characteristics by flow cytometry of gated Thy1.1+CD4+ and Thy1.1+CD4– (CD8+) donor cells. (b–g) Groups of C57BL/6 mice were untreated or sublethally irradiated and challenged with melanoma cells. The irradiated mice were then transfused with 5 × 107 syngeneic B6.PL LN cells. Immunohistochemistry of residual tumors in transfused (b, d, f) mice compared with large tumors of untreated controls (c, e, g) is shown at day 60. Staining with an anti-Thy1.1 Ab (OX-7) reveals donor cells in the regressed tumor tissue of the LN cell–transfused irradiated host (b), but not in the progressing melanoma tumor of transfused, nonirradiated animals (c). Staining for CD4+ cells demonstrates considerable infiltration in the irradiated reconstituted group (d), but minor infiltration in the nonirradiated, nonreconstituted mice (e). Similarly, CD8+ cells are found in higher numbers in irradiated and transfused (f) than in nonirradiated, nontransfused (g) mice. Staining for CD56 did not reveal appearance of NK cells (not shown).
Follow JCI:
Copyright © 2021 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts